Goodwin continues its ascent as the law firm for the new global economy. Uniquely positioned at the intersection of private equity, technology and life sciences industries, Goodwin’s lawyers have become the go-to advisors for sophisticated dealmakers, investors and companies around the world.
Mergermarket’s latest league tables tell the story. Goodwin earned top spots across a number of categories and regions, moving into the leading positions and demonstrating that its platform is in more demand than ever before. The firm’s rankings (awarded by deal count) are as follows:
- #2 in global buyouts and exits
- #2 in U.S. buyouts and exits
- #2 in U.S. buyouts
- #3 in U.S. M&A deals
- #3 in Americas M&A deals
- #4 in global M&A deals
“As the latest league tables show, the Goodwin platform is like no other,” said A.J. Weidhaas, Co-Chair of Goodwin’s Private Equity practice. “Innovation across some of the most exciting sectors of the global economy – from technology to life sciences to healthcare and beyond – is moving at breakneck speeds. It is also attracting more and more sophisticated investors. The convergence of capital and innovation requires advisors who are equally fluent in both worlds. At Goodwin, we have assembled a global team that we believe is unique in our industry – a team that is equally proficient in advising the innovators and the investors across the private equity, technology and life sciences sectors.”
Goodwin’s internationally recognized Private Equity practice focuses on buyouts, recapitalizations, growth equity investments, and portfolio company transactions in the United States and internationally with a leading position in the U.S. middle markets and growth equity. With a team of more than 200 lawyers, the practice covers the full life cycle of clients’ investments – from fund formations to exits and everything in between.
Goodwin’s Technology Companies practice is one of the largest and most recognized technology practices in the United States. Consistently rated in the top five most active of all law firms for venture capital, IPOs and M&A, the practice draws on its deep experience and network of clients and investors to provide the most effective and efficient counsel for today’s emerging companies.
Goodwin’s Life Sciences practice was named “Practice Group of the Year” for the past two years by Law360, which called Goodwin “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” The firm has also been recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year” for five out of last six years and as the “2017 IP Law Firm of the Year” by LMG Life Sciences.